Share price · PTN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PTN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Oct 2026-12.5%
Nothing announced by PTN that day or the session before.
- 16 Sep 2026-13.5%
Nothing announced by PTN that day or the session before.
- 15 Sep 2026-18.1%
Nothing announced by PTN that day or the session before.
- 1 Sep 2026+15.5%
Nothing announced by PTN that day or the session before.
- 12 Aug 2026+27.8%
Nothing announced by PTN that day or the session before.
- 29 Jun 2026-9.6%
Nothing announced by PTN that day or the session before.
- 15 Jun 2026-8.2%
Nothing announced by PTN that day or the session before.
- 13 May 2026-16.0%
- 9 Dec 2025+28.6%
Nothing announced by PTN that day or the session before.
- 4 Dec 2025+28.6%
Nothing announced by PTN that day or the session before.
Share of unusual movement by asset
For each asset, the share of PTN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Melanocortin receptorsPeptide | Dry Eye Disease | |
bremelanotide(Vyleesi) | Phase 2 | MC4RPeptide | Obesity |
| Phase 2 | MC1RPeptide | Inflammatory Bowel Disease Ulcerative Colitis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| FY2026-Q3 | $3.9M | $3.5M | $10M | $4.4M | report ↗ |
Palatin Technologies reported revenue of $3.92M for FY2026 Q3, up from zero YoY, reflecting collaboration and license revenue. R&D spend was $3.52M, down 6.4% YoY, and cash and equivalents totaled $10.16M. The company recorded a net loss of $1.43M for the quarter, with a quarterly net burn of $4.4M.
The company highlighted its melanocortin receptor platform, including Boehringer Ingelheim’s August 2025 acquisition of certain Palatin intellectual property, and projected IND filings for its obesity program: a once-weekly MC4R agonist in Q4 calendar 2026 and an oral small-molecule MC4R agonist in 1H calendar 2027. PL8177, an oral MC1R formulation for ulcerative colitis, reported positive topline Phase 2 data in Q1 2025, and an MCR agonist for diabetic nephropathy reported positive topline data in Q4 2024. Management stated that existing cash is expected to fund operations through the next twelve months.
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $3.5M | $10M | $1.4M-$4.4M operating cash flow | report ↗ |
| 2025-Q4 | — | $4.3M | $14M | $7.3M-$4.8M operating cash flow | report ↗ |
| 2025-Q3 | $8.8M | $2.5M | $1.3M | —-$1.6M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $3.8M | $2.5M | $4.8M-$5.3M operating cash flow | report ↗ |
| 2024-Q4 | — | $3.4M | $3.4M | $2.4M-$4.8M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $5.7M | $2.4M | $7.8M-$7.0M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $7.2M | $10M+ $0 short-term inv. | $8.4M-$8.6M operating cash flow | report ↗ |
| 2023-Q4 | $2.0M | $5.5M | $9.5M+ $0 short-term inv. | $7.8M-$10M operating cash flow | report ↗ |
| 2023-Q3 | $2.1M | $5.0M | $5.5M+ $0 short-term inv. | $5.9M-$5.9M operating cash flow | report ↗ |
| 2023-Q1 | $1.2M | $4.8M | $20M | $7.2M-$1.4M operating cash flow | report ↗ |
| 2022-Q4 | $1.0M | $4.4M | $21M | $1.4M-$17M operating cash flow | report ↗ |
| 2022-Q3 | $0.9M | $6.0M | $21M | $8.3M-<$0.1M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $5.0M | $38M | $7.6M-$9.5M operating cash flow | report ↗ |
| 2021-Q4 | $0.3M | $5.4M | $47M | $8.7M-$6.3M operating cash flow | report ↗ |
| 2021-Q3 | $0.2M | $3.5M | $53M | $7.1M-$6.4M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $8.8M | $12M | $7.5M | $2.1M-$14M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $15M | $2.6M | $4.3M-$21M operating cash flow | report ↗ |
| 2024-FY | $4.5M | $22M | $9.5M+ $0 short-term inv. | $7.4M-$31M operating cash flow | report ↗ |
| 2023-FY | $4.8M | $23M | $8.0M+ $3.0M short-term inv. | $6.9M-$28M operating cash flow | report ↗ |
| 2022-FY | $1.5M | $21M | $30M+ $0 short-term inv. | $9.1M<$0.1M operating cash flow | report ↗ |
| 2021-FY | -$0.2M | $13M | $60M | $8.4M-$23M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($9K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-03 | PRENDERGAST JOHN K A · director | Code Z (derivative) | 2,900 | — | — | Form 4 |
| 2026-08-03 | DUNTON ALAN W · director | Code Z (derivative) | 2,200 | — | — | Form 4 |
| 2026-08-03 | Morris Arlene · director | Code Z (derivative) | 2,400 | — | — | Form 4 |
| 2026-07-15 | WILLS STEPHEN T · Executive VP and CFO/COO | Tax withholding | 22 | $11.77 | $259 | Form 4 |
| 2026-07-15 | SPANA CARL · director, President and CEO | Tax withholding | 33 | $11.77 | $388 | Form 4 |
| 2026-07-15 | WILLS STEPHEN T · Executive VP and CFO/COO | Tax withholding | 79 | $11.72 | $926 | Form 4 |
| 2026-07-15 | SPANA CARL · director, President and CEO | Tax withholding | 119 | $11.72 | $1K | Form 4 |
| 2026-07-15 | WILLS STEPHEN T · Executive VP and CFO/COO | Tax withholding | 94 | $14.34 | $1K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 0.8M shares ($13.4M, 43.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Driehaus Capital Management LLC | 166,713 | $2.9M |
| 2 | JANUS HENDERSON GROUP PLC | 140,000 | $2.4M |
| 3 | Logos Global Management LP | 140,000 | $2.4M |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 70,000 | $1.2M |
| 5 | PERCEPTIVE ADVISORS LLC | 61,945 | $1.1M |
| 6 | Balyasny Asset Management L.P. | 41,169 | $717K |
| 7 | SUPERSTRING CAPITAL MANAGEMENT LP | 35,969 | $627K |
| 8 | MORGAN STANLEY | 27,272 | $475K |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 18,979 | $331K |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 18,502 | $322K |
| 11 | Miller Financial Services LLC | 12,600 | $219K |
| 12 | LPL Financial LLC | 12,555 | $219K |
| 13 | CITADEL ADVISORS LLC | 11,091 | $193K |
| 14 | VANGUARD FIDUCIARY TRUST CO | 8,774 | $153K |
| 15 | UBS Group AG | 3,329 | $58K |